FDA panel backs Regeneron wet AMD drug, all eyes on pricing
This article was originally published in Scrip
Executive Summary
Already rivaled by its own, much cheaper drug Avastin (bevacizumab), Roche unit Genentech could soon face another tough competitor for its vision-loss medication Lucentis (ranibizumab) if the US FDA takes the unanimous advice of its panel of outside experts to approve Regeneron's Eylea (aflibercept) to treat neovascular (wet) age-related macular degeneration (AMD).